BRPI0616476A2 - uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica - Google Patents
uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica Download PDFInfo
- Publication number
- BRPI0616476A2 BRPI0616476A2 BRPI0616476-5A BRPI0616476A BRPI0616476A2 BR PI0616476 A2 BRPI0616476 A2 BR PI0616476A2 BR PI0616476 A BRPI0616476 A BR PI0616476A BR PI0616476 A2 BRPI0616476 A2 BR PI0616476A2
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- use according
- hcv
- carbon atoms
- compound
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 21
- -1 hydroxy, amino Chemical group 0.000 claims 12
- 125000004432 carbon atom Chemical group C* 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 108091005804 Peptidases Proteins 0.000 claims 6
- 239000004365 Protease Substances 0.000 claims 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 239000002777 nucleoside Substances 0.000 claims 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 6
- 108010036949 Cyclosporine Proteins 0.000 claims 5
- 108060004795 Methyltransferase Proteins 0.000 claims 5
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims 5
- 229960001265 ciclosporin Drugs 0.000 claims 5
- 229930182912 cyclosporin Natural products 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229960000329 ribavirin Drugs 0.000 claims 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 102000002689 Toll-like receptor Human genes 0.000 claims 2
- 108020000411 Toll-like receptor Proteins 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- KWAIYQAHLXWVKC-WDCZJNDASA-N (1r,2s,5s)-3-azabicyclo[3.1.0]hexane-2-carboxamide Chemical group NC(=O)[C@H]1NC[C@H]2C[C@@H]12 KWAIYQAHLXWVKC-WDCZJNDASA-N 0.000 claims 1
- IRZRJANZDIOOIF-GAJNKVMBSA-N (2r,3r,4r,5r)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C=C1 IRZRJANZDIOOIF-GAJNKVMBSA-N 0.000 claims 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 1
- VBRUONUESYTIDA-UHFFFAOYSA-N 2-(4-fluorophenyl)-6-(methanesulfonamido)-n-methyl-5-propan-2-yloxy-1-benzofuran-3-carboxamide Chemical compound O1C2=CC(NS(C)(=O)=O)=C(OC(C)C)C=C2C(C(=O)NC)=C1C1=CC=C(F)C=C1 VBRUONUESYTIDA-UHFFFAOYSA-N 0.000 claims 1
- JXZYSNWHGBGZAI-GOSISDBHSA-N 2-[(1r)-5-cyano-8-methyl-1-propyl-4,9-dihydro-3h-pyrano[3,4-b]indol-1-yl]acetic acid Chemical compound N1C2=C(C)C=CC(C#N)=C2C2=C1[C@@](CCC)(CC(O)=O)OCC2 JXZYSNWHGBGZAI-GOSISDBHSA-N 0.000 claims 1
- QRKDOAWSBBGNLE-UHFFFAOYSA-N 2h-1,2,4-benzothiadiazine Chemical compound C1=CC=C2N=CNSC2=C1 QRKDOAWSBBGNLE-UHFFFAOYSA-N 0.000 claims 1
- WTDWVLJJJOTABN-UHFFFAOYSA-N 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide Chemical compound C1=C2C(C(=O)NC)=C(C=3C=CC(F)=CC=3)OC2=CC(N(CCO)S(C)(=O)=O)=C1C1CC1 WTDWVLJJJOTABN-UHFFFAOYSA-N 0.000 claims 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- FZRKAZHKEDOPNN-UHFFFAOYSA-N Nitric oxide anion Chemical compound O=[N-] FZRKAZHKEDOPNN-UHFFFAOYSA-N 0.000 claims 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 1
- HTJGLYIJVSDQAE-VWNXEWBOSA-N [(1s,6s,7s,8r,8ar)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate Chemical group O[C@H]1[C@H](O)[C@@H](OC(=O)CCC)CN2CC[C@H](O)[C@@H]21 HTJGLYIJVSDQAE-VWNXEWBOSA-N 0.000 claims 1
- ZWELIJXAKMASLK-UGKPPGOTSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(5-amino-2-oxo-[1,3]thiazolo[4,5-d]pyrimidin-3-yl)-2-(hydroxymethyl)oxolan-3-yl] acetate Chemical group CC(=O)O[C@@H]1[C@H](OC(=O)C)[C@@H](CO)O[C@H]1N1C(=O)SC2=CN=C(N)N=C21 ZWELIJXAKMASLK-UGKPPGOTSA-N 0.000 claims 1
- TVRCRTJYMVTEFS-ICGCPXGVSA-N [(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)-4-methyloxolan-3-yl] (2s)-2-amino-3-methylbutanoate Chemical group C[C@@]1(O)[C@H](OC(=O)[C@@H](N)C(C)C)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 TVRCRTJYMVTEFS-ICGCPXGVSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 229950003414 celgosivir Drugs 0.000 claims 1
- PJZPDFUUXKKDNB-KNINVFKUSA-N ciluprevir Chemical group N([C@@H]1C(=O)N2[C@H](C(N[C@@]3(C[C@H]3\C=C/CCCCC1)C(O)=O)=O)C[C@H](C2)OC=1C2=CC=C(C=C2N=C(C=1)C=1N=C(NC(C)C)SC=1)OC)C(=O)OC1CCCC1 PJZPDFUUXKKDNB-KNINVFKUSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 235000013902 inosinic acid Nutrition 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229940002988 pegasys Drugs 0.000 claims 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 claims 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 claims 1
- 229940106366 pegintron Drugs 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 239000013037 reversible inhibitor Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001612 ursodeoxycholic acid group Chemical group 0.000 claims 1
- 229960001661 ursodiol Drugs 0.000 claims 1
- 229950002810 valopicitabine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72267905P | 2005-09-30 | 2005-09-30 | |
| US60/722679 | 2005-09-30 | ||
| US78754906P | 2006-03-29 | 2006-03-29 | |
| US60/787549 | 2006-03-29 | ||
| PCT/US2006/038823 WO2007041632A2 (en) | 2005-09-30 | 2006-10-02 | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0616476A2 true BRPI0616476A2 (pt) | 2011-06-21 |
Family
ID=37906852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0616476-5A BRPI0616476A2 (pt) | 2005-09-30 | 2006-10-02 | uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7754685B2 (OSRAM) |
| EP (1) | EP1933859A2 (OSRAM) |
| JP (1) | JP5517454B2 (OSRAM) |
| KR (1) | KR20080059270A (OSRAM) |
| CN (1) | CN105169369B (OSRAM) |
| AU (1) | AU2006299426B2 (OSRAM) |
| BR (1) | BRPI0616476A2 (OSRAM) |
| CA (1) | CA2623865A1 (OSRAM) |
| IL (1) | IL190478A0 (OSRAM) |
| NZ (1) | NZ567262A (OSRAM) |
| RU (1) | RU2440822C2 (OSRAM) |
| WO (1) | WO2007041632A2 (OSRAM) |
| ZA (1) | ZA200803493B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2583494C (en) * | 2004-10-01 | 2014-01-21 | Scynexis, Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection |
| US7196161B2 (en) * | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| DE602006020152D1 (de) * | 2005-09-30 | 2011-03-31 | Scynexis Inc | Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion |
| KR20080059270A (ko) | 2005-09-30 | 2008-06-26 | 싸이넥시스, 인크. | Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물 |
| CN101511357B (zh) | 2006-05-19 | 2011-11-02 | 西尼克斯公司 | 环孢菌素类化合物及其组合物在制备治疗和预防眼部疾病的药物中的应用 |
| EP2027761A1 (fr) * | 2006-06-02 | 2009-02-25 | Claude Annie Perrichon | Gestion des electrons actifs |
| CA2659461A1 (en) * | 2006-08-25 | 2008-02-28 | Wyeth | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
| WO2008069917A2 (en) | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
| WO2008127613A1 (en) * | 2007-04-11 | 2008-10-23 | Scynexis, Inc. | New pharmaceutical compositions |
| CN101815533A (zh) | 2007-05-04 | 2010-08-25 | 弗特克斯药品有限公司 | 用于治疗hcv感染的组合治疗 |
| EP2116602A1 (en) | 2008-05-07 | 2009-11-11 | Institut Gustave Roussy | Combination products for treating cancer |
| US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
| US9090671B2 (en) * | 2008-06-06 | 2015-07-28 | Scynexis, Inc. | Macrocyclic peptides |
| KR101068160B1 (ko) * | 2008-12-30 | 2011-09-27 | 건국대학교 산학협력단 | Ｃ형 간염 바이러스 ｒｎａ핵산 중합효소의 활성을 저해하는 신규 플라보놀 유도체 |
| CA2748389A1 (en) * | 2008-12-31 | 2010-07-08 | Scynexis, Inc. | Derivatives of cyclosporin a |
| MX2011007194A (es) * | 2009-01-07 | 2013-07-12 | Scynexis Inc | Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc). |
| US20120301463A1 (en) | 2009-09-30 | 2012-11-29 | President And Fellows Of Harvard College | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products |
| AU2012285973A1 (en) | 2011-07-15 | 2014-01-30 | Basf Se | Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests I |
| RU2639388C1 (ru) * | 2016-10-11 | 2017-12-21 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России | Композиция для терапии вирусного гепатита С |
| WO2020037530A1 (en) * | 2018-08-22 | 2020-02-27 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Crystalline form of compound and uses thereof in medicine |
| AU2021256222A1 (en) * | 2020-04-15 | 2022-10-06 | Farsight Medical Technology (Shanghai) Co., Ltd. | Prevention and treatment of organ injuries |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022896A1 (fr) * | 1993-03-31 | 1994-10-13 | Tokyo Tanabe Company Limited | Ameliorant de la cholestase |
| AU688344B2 (en) * | 1993-07-19 | 1998-03-12 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Hepatitis C virus proliferation inhibitor |
| CN1141317C (zh) * | 1995-07-17 | 2004-03-10 | 碳化学公司 | 有抗人体免疫缺损病毒作用的环孢菌素衍生物 |
| FR2757521B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757520B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
| FR2757522B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2762843B1 (fr) * | 1997-04-30 | 1999-12-10 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2772768B1 (fr) | 1997-12-19 | 2000-01-14 | Rhone Poulenc Rorer Sa | Nouveau procede de preparation de derives de cyclosporine |
| DE69912952T2 (de) * | 1998-06-12 | 2004-09-02 | C-Chem Ag | Cyclosporine |
| FR2780061B1 (fr) | 1998-06-22 | 2001-09-07 | Rhone Poulenc Rorer Sa | Nouveau procede de preparation de derives de cyclosporine |
| AU759480B2 (en) | 1998-07-01 | 2003-04-17 | Debiopharm S.A. | Novel cyclosporin with improved activity profile |
| DE69822814T2 (de) * | 1998-08-18 | 2005-01-27 | Panacea Biotec Ltd. | Zusammensetzung enthaltend Cyclosporin in einem hydrophilen Träger |
| TR200103147T1 (tr) | 1999-12-27 | 2002-06-21 | Japan Tobacco Inc. | Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı. |
| SI1385870T1 (sl) * | 2000-07-21 | 2010-08-31 | Schering Corp | Peptidi kot NS3-serin proteazni inhibitorji virusa hepatitisa C |
| US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| NZ533628A (en) * | 2001-11-27 | 2006-07-28 | Anadys Pharmaceuticals Inc | 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof |
| US6987090B2 (en) * | 2002-05-09 | 2006-01-17 | Lg Household & Health Care Ltd. | Use of 3-position cyclosporin derivatives for hair growth |
| KR20040039622A (ko) | 2002-11-04 | 2004-05-12 | 주식회사 엘지생활건강 | 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제 |
| MXPA04012802A (es) * | 2002-06-28 | 2005-04-19 | Idenix Cayman Ltd | Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae. |
| WO2005000308A2 (en) | 2003-05-15 | 2005-01-06 | Rigel Pharmaceuticals, Inc. | Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c |
| AR044694A1 (es) * | 2003-06-17 | 2005-09-21 | Schering Corp | Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo |
| GB0320638D0 (en) * | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| ATE497775T1 (de) | 2004-07-14 | 2011-02-15 | Novartis Pharma Gmbh | Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv) |
| US20060025267A1 (en) * | 2004-07-29 | 2006-02-02 | Mircea Gradu | Differential with torque vectoring capabilities |
| CA2583494C (en) | 2004-10-01 | 2014-01-21 | Scynexis, Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection |
| HRP20110169T1 (hr) * | 2004-10-01 | 2011-04-30 | Debiopharm S.A. | Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c |
| US7196161B2 (en) * | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| KR20070087624A (ko) | 2004-12-23 | 2007-08-28 | 노파르티스 아게 | Ｈｃｖ 치료용 조성물 |
| CN101084005A (zh) | 2004-12-23 | 2007-12-05 | 诺瓦提斯公司 | 用于黄病毒科治疗的化合物 |
| US7473688B2 (en) * | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| KR20080059270A (ko) | 2005-09-30 | 2008-06-26 | 싸이넥시스, 인크. | Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물 |
| DE602006020152D1 (de) | 2005-09-30 | 2011-03-31 | Scynexis Inc | Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion |
| CN101511357B (zh) | 2006-05-19 | 2011-11-02 | 西尼克斯公司 | 环孢菌素类化合物及其组合物在制备治疗和预防眼部疾病的药物中的应用 |
| WO2008069917A2 (en) | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
| WO2008127613A1 (en) | 2007-04-11 | 2008-10-23 | Scynexis, Inc. | New pharmaceutical compositions |
| WO2008143996A1 (en) | 2007-05-18 | 2008-11-27 | Scynexis, Inc. | New chemical processes |
-
2006
- 2006-10-02 KR KR1020087010363A patent/KR20080059270A/ko not_active Abandoned
- 2006-10-02 CA CA002623865A patent/CA2623865A1/en not_active Abandoned
- 2006-10-02 JP JP2008533792A patent/JP5517454B2/ja not_active Expired - Fee Related
- 2006-10-02 RU RU2008117157/15A patent/RU2440822C2/ru not_active IP Right Cessation
- 2006-10-02 WO PCT/US2006/038823 patent/WO2007041632A2/en not_active Ceased
- 2006-10-02 NZ NZ567262A patent/NZ567262A/en not_active IP Right Cessation
- 2006-10-02 AU AU2006299426A patent/AU2006299426B2/en not_active Ceased
- 2006-10-02 CN CN201510211763.5A patent/CN105169369B/zh active Active
- 2006-10-02 US US11/542,930 patent/US7754685B2/en not_active Expired - Fee Related
- 2006-10-02 BR BRPI0616476-5A patent/BRPI0616476A2/pt not_active IP Right Cessation
- 2006-10-02 EP EP06816231A patent/EP1933859A2/en not_active Withdrawn
-
2008
- 2008-03-27 IL IL190478A patent/IL190478A0/en not_active IP Right Cessation
- 2008-04-21 ZA ZA2008/03493A patent/ZA200803493B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7754685B2 (en) | 2010-07-13 |
| ZA200803493B (en) | 2009-12-30 |
| AU2006299426B2 (en) | 2012-07-26 |
| NZ567262A (en) | 2011-12-22 |
| IL190478A0 (en) | 2008-11-03 |
| CA2623865A1 (en) | 2007-04-12 |
| EP1933859A2 (en) | 2008-06-25 |
| AU2006299426A1 (en) | 2007-04-12 |
| CN105169369A (zh) | 2015-12-23 |
| CN105169369B (zh) | 2019-10-18 |
| JP2009510129A (ja) | 2009-03-12 |
| RU2440822C2 (ru) | 2012-01-27 |
| RU2008117157A (ru) | 2009-11-10 |
| WO2007041632A2 (en) | 2007-04-12 |
| WO2007041632A3 (en) | 2007-12-13 |
| JP5517454B2 (ja) | 2014-06-11 |
| US20070173440A1 (en) | 2007-07-26 |
| KR20080059270A (ko) | 2008-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0616476A2 (pt) | uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica | |
| JP5322647B2 (ja) | ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体 | |
| JP5139065B2 (ja) | Ｃ型肝炎感染の治療及び予防のための３−エーテル及び３−チオエーテル置換シクロスポリン誘導体 | |
| US7576057B2 (en) | Cyclic peptides | |
| US20080255038A1 (en) | Pharmaceutical compositions | |
| US7196161B2 (en) | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection | |
| JP5820722B2 (ja) | シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用 | |
| US20110144005A1 (en) | Novel cyclic peptides | |
| CN102307892A (zh) | 环孢菌素a的衍生物 | |
| US20090306033A1 (en) | Novel cyclic peptides | |
| KR20120125610A (ko) | 시클로스포린 유사체 | |
| CN101068829B (zh) | 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物 | |
| CN101316606B (zh) | 治疗和预防丙型肝炎感染的方法和药物组合物 | |
| HK1125953A (en) | Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection | |
| HK1108703B (en) | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |